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Abstract
Background: Human immunodeficiency virus (HIV)-associated tuberculosis deaths have decreased worldwide over
the past decade. We sought to evaluate the effect of HIV status on tuberculosis mortality among patients undergoing
treatment for tuberculosis in Lima, Peru, a low HIV prevalence setting.
Methods: We conducted a prospective cohort study of patients treated for tuberculosis between 2005 and 2008 in
two adjacent health regions in Lima, Peru (Lima Ciudad and Lima Este). We constructed a multivariate Cox proportional
hazards model to evaluate the effect of HIV status on mortality during tuberculosis treatment.
Results: Of 1701 participants treated for tuberculosis, 136 (8.0 %) died during tuberculosis treatment. HIV-positive
patients constituted 11.0 % of the cohort and contributed to 34.6 % of all deaths. HIV-positive patients were
significantly more likely to die (25.1 vs. 5.9 %, P < 0.001) and less likely to be cured (28.3 vs. 39.4 %, P = 0.003).
On multivariate analysis, positive HIV status (hazard ratio [HR] = 6.06; 95 % confidence interval [CI], 3.96–9.27),
unemployment (HR = 2.24; 95 % CI, 1.55–3.25), and sputum acid-fast bacilli smear positivity (HR = 1.91; 95 % CI,
1.10–3.31) were significantly associated with a higher hazard of death.
Conclusions: We demonstrate that positive HIV status was a strong predictor of mortality among patients treated
for tuberculosis in the early years after Peru started providing free antiretroviral therapy. As HIV diagnosis and
antiretroviral therapy provision are more widely implemented for tuberculosis patients in Peru, future operational
research should document the changing profile of HIV-associated tuberculosis mortality.
Keywords: Tuberculosis, Human immunodeficiency virus, Clinical outcomes, Mortality, Prospective cohort study,
Operational research
Background
The global number of human immunodeficiency virus
(HIV)-associated tuberculosis (TB) deaths has been de-
creasing since 2004 [1]. The epidemic of TB/HIV co-
infection has prompted increased attention to and guidance
for integrated delivery of HIV and TB services [2, 3]. Early
antiretroviral therapy (ART) has been associated with
improved survival among adults co-infected with HIV and
TB in various settings [4–9].
In Peru, the prevalence of HIV among adults was esti-
mated to be low at 0.5 % in 2005 [10]. However, only
1.9 % of all Peruvian TB patients had a known HIV sta-
tus in 2005, and 1.2 % of known HIV-positive TB pa-
tients were on ART in 2010 [11]. During this period,
Peru implemented aggressive tuberculosis control strat-
egies, including rapid diagnosis and individualized regi-
mens for MDR-TB [12, 13]. While there have been
significant gains in diagnosis of HIV and ART provision
for TB/HIV co-infected patients worldwide, particularly
in high HIV prevalence settings, we sought to quantify
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the effect of HIV status on TB mortality in this low HIV
prevalence setting. Our objective in the present study
was to evaluate the impact of HIV on mortality in the
early years after Peru started providing free ART, among
a large prospective cohort of patients who underwent
treatment for TB in two health regions of Lima, Peru.
Methods
Setting and enrollment
Between 2005 and 2010, the estimated incidence of TB
in Peru was 140 and 106 cases per 100,000 population,
respectively [11]. The HIV prevalence among Peruvian
adults dropped during this period from 0.5 to 0.4 %, and
patients co-infected with HIV comprised 1.9 to 2.6 % of
notified TB cases [10, 11]. The enrollment methods for
this cohort have been described previously [12, 14, 15]. In
brief, we enrolled all patients with confirmed TB or pre-
sumptive TB with respiratory symptoms for at least 2
weeks who were living in 2 adjacent health regions in Lima
(Lima Ciudad and Lima Este), and who met Peruvian
National Tuberculosis Control Program (NTP) criteria for
drug-susceptibility testing (DST) referral (Table 1) [13].
The criteria for DST referral detailed in Table 1 reflected a
targeted testing strategy for patients at risk for multidrug-
resistant TB (MDR-TB) [14]. Healthcare workers at local
health establishments identified patients and sent their
sputum samples to the reference laboratory for DST. Be-
cause all sputum samples for DST were sent to the district
laboratories, we identified subjects eligible for enrollment
by this referral. We enrolled patients at the time of sputum
sample collection for culture and DST, from January 5,
2005 through March 5, 2008 in Lima Ciudad and from
April 20, 2005 through May 27, 2008 in Lima Este. Study
personnel visited each district laboratory on a regular basis
to review sample referrals and confirm that all eligible sub-
jects had been identified. There were no exclusion criteria
for enrollment into the study.
Data collection
A trained team collected data prospectively from HIV and
TB charts, laboratory registries, and databases using stan-
dardized forms. Baseline sociodemographic and clinical
data, including baseline HIV status, were collected at en-
rollment. For HIV-positive patients, study personnel re-
corded the most recent CD4 cell count result and date, as
well as receipt of ART, upon enrollment. HIV viral loads
were not consistently available for this analysis. TB physi-
cians reviewed all available chest x-rays (CXR) performed
less than 1 year before and up to 1 month after enrollment,
using standardized criteria for coding radiographic abnor-
malities. For each lung field, TB physicians recorded the
presence of cavities, fibrosis, alveolar infiltrates, pneumo-
thorax, pleural hemorrhage, nodules, disseminated/miliary
disease, bullae, thoracic lymphadenopathy, and post-
surgical changes. Data were entered into an Epi Info ver-
sion 3.4.3 database (Centers for Disease Control and Pre-
vention, Atlanta, GA, USA) and exported into an Access
2000 database (Microsoft Corporation, Redmond, WA,
USA).
Table 1 Peruvian National TB Control Program criteria for DST
referral
A. Smear- or culture-positive patients at risk for MDR-TB without prior
treatment history
Subjects may be referred for DST if they 1) are diagnosed with smear-
positive pulmonary TB, 2) have no prior history of anti-tuberculosis
treatment, and 3) have at least one of the following risk factors:
1. Household contact of patient with documented MDR-TB or
presumptive MDR-TB (i.e., in treatment with second-line drugs,
failed anti-tuberculosis treatment or died of TB in past 2 years)
2. HIV-positive by ELISA and Western Blot confirmation
3. Diabetes mellitus
4. Healthcare worker by profession, regardless of health care field,
in the last 2 years
5. Student of health sciences in the past 2 years
6. Incarcerated or employee of the penitentiary system in the past
2 years
7. Chronic treatment with corticosteroids
8. Other condition of immunosuppression
9. Adverse reaction to TB medications that has required a change
in regimen
10. Hospitalization for any indication in the past 2 years lasting
more than 15 days
11. Presumptive treatment failure of Category I or II regimen
(i.e., smear- or culture-positive between 2 and 4 months of
treatment)
B. Patients who have received at least one previous course of treatment
Subjects may be referred for DST if they have any of the prior TB
treatment histories:
1. Lost to follow-up for any previous regimen and now present for
retreatment
2. Relapsed after completion of any previous regimen within less
than 6 months
3. Treatment failed with any previous regimen
4. Received multiple courses of anti-tuberculosis treatment
5. Have a history of private or self-administered treatment
C. Confirmed or presumptive smear-negative TB among high-risk groups
(tested by BACTEC™)
Subjects may be referred for DST if they 1) have presumptive or
confirmed active pulmonary TB, 2) are smear-negative, and 3) have at
least one of the following risk factors:
1. Pediatric household contact of patient with documented MDR-TB
2. Pediatric household contact of patient who has died of TB
within the past 2 years
3. HIV-positive by ELISA and Western Blot confirmation
DST drug susceptibility testing, ELISA enzyme-linked immunosorbent assay,
HIV human immunodeficiency virus, MDR-TB multidrug-resistant tuberculosis,
TB tuberculosis
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Drug susceptibility testing methods
The DST methods for this cohort have been described
previously [12, 14, 16, 17]. Under program conditions,
the Peruvian National Reference Laboratory (NRL) per-
formed mycobacterial culture and DST using the BAC-
TEC™ 460 system (Becton, Dickinson and Company,
Sparks, MD, USA) on paucibacillary and smear-negative
samples produced by high-risk patients (HIV-positive,
children, healthcare workers). Other smear-negative sam-
ples underwent mycobacterial culture on modified Ogawa
medium followed by conventional DST for first-line drugs
using the proportions method on Löwenstein-Jensen (LJ)
medium at the district laboratory. Smear-positive samples
were cultured on LJ medium and underwent DST using
the indirect agar plate proportions method. Beginning in
December 2005 in Lima Ciudad and March 2007 in Lima
Este, these samples were cultured on modified LJ medium
and tested for isoniazid and rifampicin resistance using
the direct nitrate reductase assay (NRA) method [18]. All
isolates found to be drug-resistant at the district laborator-
ies were sent to the NRL for complete DST to first- and
second-line drugs.
HIV and tuberculosis management
In 2004, the Peruvian Ministry of Health began offering
free ART through the Peruvian National HIV Program to
patients with either 1) Stage III or Stage IV acquired im-
munodeficiency syndrome (AIDS) defining illnesses other
than TB with CD4 count <350 cells/μL, or 2) Stage I or
Stage II HIV disease with CD4 count <200 cells/μL accord-
ing to World Health Organization criteria [19]. Peruvian
national TB treatment guidelines recommended HIV
screening for all TB patients [13]. HIV physicians evaluated
HIV-positive patients monthly, with CD4 and viral load
monitoring every 6 months. Peruvian national TB treat-
ment guidelines made the following recommendations re-
garding timing of ART initiation for TB/HIV co-infected
patients: 1) ART deferral until after completion of TB
treatment for those with CD4 count >200 cells/μL; 2) ART
initiation after the intensive phase of TB treatment for
those with CD4 count 100–200 cells/μL; and 3) ART initi-
ation as soon as feasible after TB treatment initiation for
those with CD4 count <100 cells/μL (with no specific rec-
ommendation for early versus deferred ART) [13].
Details of the TB management have been published
elsewhere [13, 20, 21]. New drug-susceptible TB (DS-
TB) cases, regardless of HIV status, received a biphasic
treatment regimen with first-line drugs isoniazid (H), ri-
fampicin (R), ethambutol (E), and pyrazinamide (Z):
2RHZE/4(RH)2 [13]. Retreatment DS-TB cases received
a regimen including streptomycin (S) in the intensive
phase: 2RHZES/1RHZE/5(RHE)2 [13]. Patients with pre-
sumptive MDR-TB received empiric treatment with
second-line therapy pending DST results: ethambutol,
pyrazinamide, kanamycin, ciprofloxacin, ethionamide, cy-
closerine, and para-aminosalicylic acid [13]. The guide-
lines used to design individualized MDR-TB treatment
regimens based on DST results have been described else-
where [22]. All TB patients received directly observed
treatment free of charge through the Peruvian NTP. We
followed patients until a TB treatment outcome was re-
corded or until the administrative end of the study on
June 26, 2010.
Exposure variable definitions
We identified patients as having drug-resistant TB (DR-
TB) if they had a positive culture for M. tuberculosis and
DST results showed resistance to isoniazid and/or rifam-
picin. MDR-TB was defined as drug-resistance to at least
isoniazid and rifampicin. Baseline microbiologic data was
defined as smear, culture, and DST results from samples
collected within 30 days of enrollment. If baseline drug re-
sistance data were not available for isoniazid and rifampi-
cin, the patient was considered to have no baseline DST
result. Extrapulmonary TB was defined as TB localization
in a non-pulmonary organ and/or evidence of pleural or
disseminated (miliary) TB on CXR. Baseline HIV status
was defined as positive if a positive HIV test result and/or
receipt of ART was documented in the patient’s chart.
Baseline HIV status was defined as negative if documented
as such, or if the HIV status was unknown (either due to
not being tested for HIV, or an unknown HIV test result).
The standardized forms used to abstract data from clinical
charts did not differentiate between unknown or negative
HIV status, so we were unable to ascertain the proportion
with unknown HIV status. Baseline CD4 cell count was
defined as CD4 testing performed within 6 months of
enrollment.
Outcome variable definition
We followed patients from the time of enrollment to the
date of TB treatment outcome, including death. The pa-
tients with no treatment outcome during the observa-
tion period were censored on the last day of follow-up.
We excluded patients from the analysis if they were not
treated for TB during the period of observation. TB
treatment outcomes were defined according to previ-
ously published guidelines [23, 24].
Statistical methods
We selected potential predictors of mortality from risk
factors identified in the literature and clinical experience
[9, 25–31], and evaluated them using univariate Cox
proportional hazards models. We considered predictors
associated with death on univariate analysis (P < 0.05)
for inclusion in the multivariate Cox proportional haz-
ards model evaluating the association between HIV and
mortality. We built the multivariate model using a
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backward selection method, retaining age, gender, and
predictors associated with death with a P < 0.20. Since
HIV-positive patients tended to present with more se-
vere clinical findings, we considered the possibility that
the effect of HIV status on mortality during TB treat-
ment was mediated by predictors significantly associated
with death on univariate analysis (P < 0.05) that also cor-
responded to disease severity. We considered the follow-
ing variables as potential mediators: ability to perform
activities of daily living (ADLs), low body mass index
(BMI), and dyspnea. We evaluated the direct effect of
HIV status on time to death by comparing multivariate
models with and without these variables. We tested the
proportional hazards assumption in the multivariate
models by using Schoenfeld residuals fitted to rank of
analysis time, and we constructed a Kaplan-Meier sur-
vival curve stratified by HIV group. We also performed a
secondary analysis in which we repeated the multivariate
analyses while adjusting for baseline MDR-TB.
All analyses were performed using Stata/SE version
14.1 (StataCorp LP, College Station, TX, USA). The χ2
test or Fisher’s exact test was used to calculate P values,
when appropriate. The Student’s t test was used for the
two-sample mean-comparison test, when appropriate.
All statistical tests were two-sided, and significance was
set at α = 0.05.
Ethics statement
Institutional review boards at the Partners Human Re-
search Committee and the Peruvian National Institute of
Health Committee of Research Ethics approved the ori-
ginal study protocol and the protocol amendment for
this analysis. The original study was a programmatic ef-
fort under the leadership of the Peruvian National TB
Control Program and the Peruvian National Institute of
Health. An informed consent waiver was approved from
both institutional review boards, because the data collec-
tion process required no contact with the patients; only
included information that was routinely collected in the
course of providing clinical care to patients; and the
treatment regimens administered to patients were deter-
mined by the standards of care in Peru at the time, such
that participation in the study did not adversely affect
the rights and welfare of the subjects and patient confi-
dentiality was maintained. The U.S. Centers for Disease
Control and Prevention approved this activity as pro-
gram evaluation and not human subjects research.
Results
Of the 1846 participants enrolled (Fig. 1), 145 (7.9 %)
were excluded because they were not treated for TB dur-
ing the observation period. The remaining 1701 partici-
pants were included in the analysis; 187 (11.0 %) were
HIV-positive (Table 2). HIV-positive patients were more
likely to be male, unemployed, and have a history of al-
cohol or illicit drug abuse compared with HIV-negative
patients. HIV-positive patients tended to experience a
shorter mean duration of TB symptoms before DST re-
ferral (2.5 ± 3.0 vs. 3.5 ± 4.9 months), but presented with
more severe clinical findings such as weight loss, low
BMI, dyspnea, and poor functional status in terms of
ability to perform ADLs. They were also more likely to
present with extrapulmonary TB and fewer pulmonary
findings (abnormal CXR, cavitary disease, hemoptysis,
sputum acid-fast bacilli (AFB) smear positivity).
Bacteriological confirmation and hence documented
DST data were less frequently obtained among HIV-
positive individuals. Among those with DST data, the
proportion of MDR-TB was lower for HIV-positive ver-
sus HIV-negative individuals (11.8 vs. 25.5 %, P < 0.001).
Fig. 1 Study flow
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Table 2 Characteristics of patients treated for tuberculosis, by HIV status*
Characteristic HIV positive HIV negative Total
(N = 187) (N = 1514) (N = 1701)
No. (%) No. (%) No. (%)
Sociodemographic characteristics
Age (years), mean ± SD 33.4 ± 10.6 33.6 ± 15.9 33.6 ± 15.4
Female gender 49 (26.2) 551 (36.4) 600 (35.3)
Married or lived together 64 (34.2) 554 (36.6) 618 (36.3)
Unemployed 102 (54.6) 535 (35.3) 637 (37.5)
Did not begin secondary level education, n = 1700 30 (16.0) 318 (21.0) 348 (20.5)
Tobacco use, n = 1699a 59 (31.9) 382 (25.2) 441 (26.0)
Alcohol abuse, n = 1699b 85 (46.0) 537 (35.5) 622 (36.6)
Illicit drug abuse, n = 1699c 57 (30.7) 252 (16.7) 309 (18.2)
Comorbidities
Diabetes mellitus 1 (0.5) 182 (12.0) 183 (10.8)
Chronic corticosteroid therapy 0 (0) 6 (0.4) 6 (0.4)
Other immunosuppression 0 (0) 8 (0.5) 8 (0.5)
TB history and risk exposures
Previously treated for TB 161 (86.1) 1326 (87.6) 1487 (87.4)
Prior incarceration, n = 1695d 17 (9.2) 106 (7.0) 123 (7.3)
Recent hospitalization for >15 daysd 2 (1.1) 14 (0.9) 16 (0.9)
Healthcare occupational exposured,e 1 (0.5) 84 (5.6) 85 (5.0)
Clinical presentation, all patients
Duration of symptoms before DST solicited (months),mean ± SD, n = 1690 2.5 ± 3.0 3.5 ± 4.9 3.4 ± 4.8
Able to perform ADLs 149 (79.7) 1424 (94.1) 1573 (92.5)
Weight loss, n = 1698 164 (89.1) 1202 (79.4) 1366 (80.5)
BMI (kg/m2), mean ± SD, n = 1693 19.9 ± 3.5 21.4 ± 3.6 21.2 ± 3.6
Dyspnea, n = 1698 49 (26.3) 246 (16.3) 295 (17.4)
Hemoptysis, n = 1699 3 (1.6) 98 (6.5) 101 (5.9)
Chest radiography
Abnormal CXR, n = 1651 135 (72.2) 1375 (90.8) 1510 (88.8)
Normal CXR, n = 1651 41 (21.9) 100 (6.6) 141 (8.3)
No CXR performed, n = 50 11 (5.9) 39 (2.6) 50 (2.9)
Cavitary disease, n = 1651 27 (15.3) 598 (40.5) 625 (37.9)
Site of TB disease
Pulmonary only 157 (84.0) 1448 (95.6) 1605 (94.4)
Extrapulmonary with or without pulmonary 30 (16.0) 66 (4.4) 96 (5.6)
Clinical presentation, HIV positive patients
Receiving ART at baseline 24 (12.8) N/A N/A
Receiving cotrimoxazole at baseline 29 (15.5)
No CD4 performed 147 (78.6) N/A N/A
Baseline CD4 count (cells/μL) if performed, n = 40 N/A N/A
< 100 13 (32.5) N/A N/A
100–350 23 (57.5) N/A N/A
> 350 4 (10.0) N/A N/A
Microbiologic data
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Among HIV-positive patients, 24 (12.8 %) were receiving
ART at baseline, 29 (15.5 %) were receiving cotrimoxa-
zole prophylaxis, and 147 (78.6 %) did not have baseline
CD4 cell count data. Two (8.3 %) of the 24 HIV-positive
patients who were receiving ART were also receiving
cotrimoxazole at baseline. Of the 40 HIV-positive pa-
tients with baseline CD4 counts, 36 (90.0 %) had base-
line CD4 lower than 350 cells/μL and 13 (32.5 %) were
below 100 cells/μL.
A total of 999 (58.7 %) patients were either cured or
completed treatment (Table 3). HIV-positive patients were
significantly more likely to die (25.1 vs. 5.9 %, P < 0.001)
and less likely to be cured (28.3 vs. 39.4 %, P = 0.003). A
Kaplan-Meier survival curve stratified by HIV group is
shown in Fig. 2. The HIV-positive patients in the cohort
contributed 47 (34.6 %) of all deaths; 42 (89.4 %) of deaths
among the HIV-positive patients occurred among those
who were not receiving ART at baseline. Among those
who died, 6 (12.8 %) HIV-positive and 16 (18.0 %) HIV-
negative patients had achieved culture conversion from
positive to negative (P = 0.433, data not shown).
The median duration of follow-up was 232 (interquar-
tile range [IQR]: 159–486) days for a total of 568,602
person-days of follow-up, during which time there were
136 deaths. Among those who died, the median survival
time was 111 (IQR: 53–263) days. In univariate analyses
Table 2 Characteristics of patients treated for tuberculosis, by HIV status* (Continued)
Baseline bacteriologically unconfirmed TB diagnosisf 58 (31.0) 51 (3.4) 109 (6.4)
Baseline sputum AFB smear positive, n = 1669 86 (50.3) 1362 (90.9) 1448 (86.8)
Baseline TB drug resistance status
Drug susceptible 74 (39.6) 576 (38.0) 650 (38.2)
Mono-resistant (either H or R) 20 (10.7) 133 (8.8) 153 (9.0)
MDR-TB 22 (11.8) 386 (25.5) 408 (24.0)
No result 71 (38.0) 419 (27.7) 490 (28.8)
Treatment course
Received second line drugs during studyg 36 (19.3) 711 (47.0) 747 (43.9)
Non-adherence, n = 1689h 46 (24.6) 376 (25.0) 422 (25.0)
ADLs activities of daily living, AFB acid-fast bacilli, ART antiretroviral therapy, BMI body mass index, CXR chest x-ray, DST drug susceptibility test, H isoniazid,
HIV human immunodeficiency virus, MDR-TB multidrug-resistant tuberculosis, R rifampicin, SD standard deviation, TB tuberculosis
*Values are presented as No. (%) unless otherwise specified. Boldface indicates statistically significant difference (P < 0.05) between the HIV positive and the HIV
negative group
aDefined as current or past tobacco use of more than 10 packs/year
bDefined as current or past alcohol use that interfered with family, health, or work
cDefined as current or past illicit drug use that interfered with family, health, or work
dDuring the past 2 years
eDefined as healthcare worker or student
fDefined as any case with a positive baseline AFB (not paucibacillary) or with a positive baseline culture
gDefined as receiving a regimen containing second-line drugs at enrollment or post enrollment
hDefined as having spent >20 % of treatment regimen duration off drugs
Table 3 Treatment outcomes of patients treated for tuberculosis, by HIV status*
Characteristic HIV positive HIV negative Total P value
(N = 187) (N = 1514) (N = 1701)
No. (%) No. (%) No. (%)
Favorable outcome 89 (47.6) 910 (60.1) 999 (58.7) 0.001
Cured 53 (28.3) 596 (39.4) 649 (38.2) 0.003
Treatment completed 36 (19.3) 314 (20.7) 350 (20.6) 0.635
Unfavorable outcome 85 (45.5) 464 (30.7) 549 (32.3) <0.001
Default 37 (19.8) 345 (22.8) 382 (22.5) 0.353
Failure 1 (0.5) 30 (2.0) 31 (1.8) 0.245
Death 47 (25.1) 89 (5.9) 136 (8.0) <0.001
Transferred out 10 (5.4) 105 (6.9) 115 (6.8) 0.415
Unknown 3 (1.6) 35 (2.3) 38 (2.2) 0.792
HIV human immunodeficiency virus
*Boldface indicates statistically significant difference (P < 0.05) between the HIV positive and the HIV negative group
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(Table 4), predictors associated with a lower hazard of
death were female gender and ability to perform ADLs
at baseline, while baseline characteristics associated with
a higher hazard of death were unemployment, substance
abuse, positive HIV status, recent hospitalization, weight
loss, low BMI, dyspnea, and lack of bacteriological con-
firmation. We were unable to estimate the effect of CD4
categories on mortality given the high proportion of
missing CD4 results among HIV-positive patients.
On multivariate analysis, we used 1699 (99.9 %) observa-
tions with complete data to build the multivariate model
(Table 5). Positive HIV status, unemployment, and baseline
sputum AFB positivity were all significantly associated
with a higher hazard of death. When we adjusted for base-
line ability to perform ADLs, low BMI, and dyspnea, we
observed that the direct effect of positive HIV status on
hazard of death was 22.9 % lower than the marginal effect
(hazard ratio [HR] = 4.67 vs. HR = 6.06, respectively). For
the secondary analysis, we repeated the multivariate ana-
lyses adjusting for baseline MDR-TB, using 1211 (71.2 %)
observations with complete DST data to build the multi-
variate model (Table 6). Baseline MDR-TB showed a trend
towards a higher hazard of death in this cohort, however
the association was not statistically significant (HR = 1.40;
95 % confidence interval [CI], 0.92–2.13). We observed that
positive HIV status and unemployment remained signifi-
cantly associated with a higher hazard of death, while the
effect of baseline sputum AFB positivity was no longer
significant (HR = 2.05; 95 % CI, 0.96–4.36; P = 0.063).
Adjusting for potential mediators, the direct effect of posi-
tive HIV status on hazard of death was 25.9 % lower than
the marginal effect (HR = 4.71 vs. HR = 6.36, respectively).
Discussion
We describe the impact of positive HIV status on mortal-
ity in a cohort of 1701 patients treated for TB in two
health regions in Lima, Peru, demonstrating that HIV-
positive patients accounted for 34.6 % of deaths and had a
six-fold higher hazard of death during TB treatment when
compared to HIV-negative patients. HIV-positive patients
presented with more severe clinical findings than HIV-
negative patients; we found that some of the effect of HIV
status on mortality was mediated by ability to perform
ADLs, low BMI, and dyspnea at the time of enrollment.
After adjusting for these markers of baseline disease sever-
ity, the direct effect of HIV status on mortality remained
significantly associated with a more than four-fold higher
hazard of death. In the secondary analysis, the observed
effect of positive HIV status on mortality was similar when
we adjusted for baseline MDR-TB. Our results are consist-
ent with prior studies showing that HIV is a predictor of
poor TB treatment outcomes in Peru [26, 27, 32–35], and
serves to highlight the need for improved management of
TB/HIV co-infection in this low HIV prevalence setting.
To our knowledge, this is the largest published prospective
cohort evaluating mortality among TB/HIV co-infected
patients in Peru.
Our finding that 78.6 % of HIV-positive patients had
missing CD4 cell count data suggested that the majority
of HIV patients were not receiving adequate HIV care at
the time of enrollment. This HIV treatment gap is also
reflected in publicly reported data from Peru, where
1.9 % of all Peruvian TB patients had a known HIV sta-
tus in 2005 and 1.2 % of known HIV-positive TB pa-
tients were on ART in 2010 [11]. We observed that 42
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Table 4 Univariate predictors associated with time to death among patients treated for tuberculosis*
Characteristic Unadjusted HR (95 % CI) P value
Sociodemographic characteristics
Pediatric casea 0.36 (0.12–1.14) 0.082
Female gender 0.65 (0.45–0.95) 0.025
Unemployed 2.95 (2.09–4.18) <0.001
Did not begin secondary level education, n = 1700 1.08 (0.71–1.65) 0.712
Substance abuse, n = 1699b 1.72 (1.23–2.41) 0.002
Comorbidities
HIV positive 5.99 (4.18–8.59) <0.001
Diabetes mellitus 0.57 (0.26–1.22) 0.146
TB history and risk exposures
Previously treated for TB 1.62 (0.90–2.93) 0.110
Prior incarceration, n = 1695c 1.07 (0.52–2.19) 0.854
Recent hospitalization for >15 daysc 4.13 (1.53–11.2) 0.005
Healthcare occupational exposurec,d 0.15 (0.02–1.08) 0.060
Clinical presentation, all patients
Duration of symptoms >3 months before
DST solicited, n = 1690
0.99 (0.70–1.41) 0.970
Weight loss, n = 1698 2.99 (1.65–5.43) <0.001
Able to perform ADLs 0.15 (0.10–0.21) <0.001
Low BMI, n = 1693e 2.38 (1.70–3.35) <0.001
Dyspnea, n = 1698 2.90 (2.04–4.11) <0.001
Hemoptysis, n = 1699 0.52 (0.21–1.26) 0.147
No CXR performed 1.59 (0.65–3.88) 0.312
Abnormal CXR, n = 1651 0.60 (0.35–1.02) 0.061
Cavitary disease, n = 1651 0.87 (0.61–1.24) 0.446
Extrapulmonary TB 1.51 (0.82–2.80) 0.188
Clinical presentation, HIV positive patients only
Receiving ART at baseline, n = 187 0.72 (0.28–1.82) 0.482
Receiving cotrimoxazole at baseline, n = 187 0.53 (0.21–1.36) 0.188
No CD4 performed, n = 187 1.25 (0.60–2.61) 0.550
Microbiologic data
Baseline bacteriologically unconfirmed TB diagnosisf 2.02 (1.14–3.59) 0.016
Baseline sputum AFB smear positive, n = 1669 0.87 (0.53–1.43) 0.589
Baseline MDR-TB, n = 1211 1.10 (0.73–1.65) 0.658
No baseline DST result 1.02 (0.70–1.51) 0.906
Treatment course
Received second line drugs during studyg 0.84 (0.57–1.23) 0.376
Non-adherence, n = 1689h 0.84 (0.56–1.25) 0.381
ADLs activities of daily living, AFB acid-fast bacilli, ART antiretroviral therapy, BMI body mass index, CI confidence interval, CXR chest x-ray, DST drug susceptibility
test, HIV human immunodeficiency virus, HR hazard ratio; MDR-TB multidrug-resistant tuberculosis, TB tuberculosis
*Boldface indicates P < 0.05. For covariates with full data, the model included n = 1701 (568,602 person-days, 136 deaths). For covariates with missing data,
the n for the model is provided
aDefined as age <15 years
bDefined as current or past alcohol use or illicit drug use that interfered with family, health, or work
cDuring the past 2 years
dDefined as healthcare worker or student
eDefined as BMI <20 kg/m2 in men, BMI <18.5 kg/m2 in women
fDefined as any case with a positive baseline AFB (not paucibacillary) or with a positive baseline culture
gDefined as receiving a regimen containing second-line drugs at enrollment or post enrollment
hDefined as having spent >20 % of treatment regimen duration off drugs
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(89.4 %) of deaths among the HIV-positive patients in
this cohort occurred among those who were not receiv-
ing ART at baseline. Since early ART has been associated
with improved survival among adults co-infected with
HIV and TB in other settings [4–9], expanded access to
early ART and retention in care could have prevented a
sizable proportion of the mortality in this cohort.
This large cohort of patients was enrolled and followed
prospectively under real program conditions. Since HIV-
positive status was an indication for DST among TB pa-
tients in Peru, our sampling strategy overrepresented
HIV-positive patients who constituted 11.0 % of the
analysis cohort. We classified the HIV-negative group as
those patients with either documented negative or un-
known HIV status. Although the standardized forms we
used to abstract data from clinical charts did not differ-
entiate between unknown or negative HIV status, we
consider this a reasonable assumption in Peru, where
only 1.9–2.6 % of notified TB cases were documented to
be HIV-positive during the study period [11]. We would
expect that nondifferential misclassification of HIV sta-
tus would bias the effect of HIV status on mortality to-
wards the null. However, this misclassification may
diminish the ability of future studies to document a
Table 5 Multivariate model examining association between HIV infection and time to death among patients treated for tuberculosis*
Characteristic Multivariate model Direct effect model
(without mediators) (with mediators)
N = 1699, 136 deaths N = 1658, 127 deaths
Adjusted HR Adjusted HR
(95 % CI) P value (95 % CI) P value
HIV positive 6.06 (3.96–9.27) <0.001 4.67 (2.99–7.29) <0.001
Pediatric casea 0.64 (0.15–2.64) 0.536 0.45 (0.11–1.90) 0.276
Female gender 0.92 (0.61–1.37) 0.670 0.96 (0.63–1.47) 0.870
Unemployed 2.24 (1.55–3.25) <0.001 1.82 (1.24–2.65) 0.002
Baseline sputum AFB smear positive 1.91 (1.10–3.31) 0.021 1.88 (1.07–3.29) 0.028
Able to perform ADLs 0.26 (0.17–0.41) <0.001
Low BMIb 1.71 (1.18–2.48) 0.004
Dyspnea 1.56 (1.04–2.34) 0.030
ADLs activities of daily living, AFB acid-fast bacilli, BMI body mass index, CI confidence interval, HIV human immunodeficiency virus, HR hazard ratio
*Boldface indicates P < 0.05. The total n for each multivariate model is lower than the analysis cohort (n = 1701) because of complete case drop of observations
with missing data
aDefined as age <15 years
bDefined as BMI <20 kg/m2 in men, BMI <18.5 kg/m2 in women
Table 6 Multivariate model examining association between HIV infection and time to death among patients treated for
tuberculosis, adjusted for baseline MDR-TB*
Characteristic Multivariate model Direct effect model
(without mediators) (with mediators)
N = 1211, 101 deaths N = 1192, 97 deaths
Adjusted HR Adjusted HR
(95 % CI) P value (95 % CI) P value
HIV positive 6.36 (3.98–10.2) <0.001 4.71 (2.87–7.73) <0.001
Pediatric casea 0.41 (0.06–3.01) 0.381 0.32 (0.04–2.37) 0.265
Female gender 0.77 (0.48–1.25) 0.288 0.84 (0.51–1.38) 0.484
Unemployed 1.95 (1.28–2.97) 0.002 1.61 (1.05–2.47) 0.029
Baseline sputum AFB smear positive 2.05 (0.96–4.36) 0.063 2.14 (1.00–4.61) 0.051
Baseline MDR-TB 1.40 (0.92–2.13) 0.121 1.37 (0.89–2.10) 0.150
Able to perform ADLs 0.27 (0.16–0.45) <0.001
Low BMIb 2.09 (1.37–3.19) 0.001
Dyspnea 1.27 (0.79–2.07) 0.326
ADLs activities of daily living, AFB acid-fast bacilli, BMI body mass index, CI confidence interval, HIV human immunodeficiency virus, HR hazard ratio, MDR-TB
multidrug-resistant tuberculosis
*Boldface indicates P < 0.05. The total n for each multivariate model is lower than the analysis cohort (n = 1701) because of complete case drop of observations
with missing data
aDefined as age <15 years
bDefined as BMI <20 kg/m2 in men, BMI <18.5 kg/m2 in women
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reduction in the magnitude of the effect of HIV status
on mortality, when compared to our estimates.
We found that baseline MDR-TB was associated with a
non-significant trend towards higher hazard of death in
this cohort. This may have been due to an existing aggres-
sive TB control strategy in Peru, including rapid diagnosis
and individualized regimens for MDR-TB. We have previ-
ously published data from this cohort suggesting that the
concurrent implementation of rapid DST in Peru was as-
sociated with favorable treatment outcome and prolonged
survival among individuals without previous anti-TB treat-
ment, and a non-significant trend towards improved out-
comes among those with drug-resistant TB [15]. Despite
the observational nature of this study, frequent visits by
our study personnel to health centers could have sensitized
healthcare workers to follow screening and treatment pro-
tocols more closely than they would have otherwise.
We also found that 12.8 % of deaths in the HIV-positive
group and 18.0 % of deaths in the HIV-negative group had
achieved culture conversion from positive to negative. A
limitation in this study is that our prospective clinical
chart reviews did not capture causes of death. We were
therefore unable to ascertain whether deaths in this cohort
were truly due to TB or due to competing risks in this
urban population in Lima, for example from comorbidi-
ties, accidental death, or violence. Deaths among those
who had achieved culture conversion may have biased the
effect of HIV status on mortality away from the null if in
fact these patients died from non-TB causes. Deaths
among those who were not treated for TB, an exclusion
criterion for this analysis, may have biased the effect of
HIV status on mortality in either direction.
Conclusions
We observed a strong influence of HIV status on mortal-
ity within the context of a National TB Program deliver-
ing rapid diagnosis and individualized regimens for
MDR-TB, but with challenges providing HIV care to co-
infected patients. These findings suggest that aggressive
strategies for TB alone were not sufficient: universal
HIV testing and timely care for those living with HIV
were also needed [36]. Future operational research will
be important to establish the changing profile of HIV-
associated TB mortality in Peru, as HIV diagnosis and
ART provision are more widely implemented.
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